Douglas Kerr Sells 1,290 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) insider Douglas Kerr sold 1,290 shares of the stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $24,355.20. Following the completion of the sale, the insider directly owned 162,564 shares of the company’s stock, valued at $3,069,208.32. This trade represents a 0.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Douglas Kerr also recently made the following trade(s):

• On Friday, September 4th, Douglas Kerr sold 3,745 shares of Dyne Therapeutics stock. The shares were sold at an average price of $24.35, for a total transaction of $91,190.75.

Dyne Therapeutics Stock Down 16.4%

Shares of NASDAQ:DYN traded down $3.97 during trading on Tuesday, reaching $20.31. 17,067,421 shares of the company traded hands, compared to its average volume of 2,151,348. The firm has a fifty day simple moving average of $24.86 and a 200 day simple moving average of $20.45. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics, Inc. has a 1-year low of $11.92 and a 1-year high of $27.31. The firm has a market cap of $3.79 billion, a P/E ratio of -6.10 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Analysts anticipate that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current fiscal year.

Dyne Therapeutics News Summary

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Dyne will present six- and 12-month ACHIEVE data at the World Muscle Society and AANEM meetings on September 30. The presentations will compare a pooled treated group with a matched natural-history cohort and include updated safety information. Topline data from the fully enrolled registrational expansion cohort remain targeted for Q1 2027. Dyne ACHIEVE data announcement
• Positive Sentiment: Z-basivarsen has received FDA Breakthrough Therapy, Orphan Drug and Fast Track designations, while Dyne is advancing the program into the Phase 3 HARMONIA trial. These regulatory designations and upcoming data could provide future catalysts if clinical benefit is confirmed.
• Neutral Sentiment: Options activity was unusually high, with traders purchasing approximately 20,532 call contracts—more than 40 times the average daily call volume. This may reflect speculative positioning ahead of clinical presentations, but it does not establish a fundamental change in the company’s outlook.
• Neutral Sentiment: Several insiders, including CEO John Cox, Chief Medical Officer Douglas Kerr and Chief Commercial Officer Johanna Friedl-Naderer, reported small stock sales. The filings state that the transactions were made to cover tax withholding obligations from vested equity awards, reducing their negative significance.
• Negative Sentiment: Investor sentiment was pressured after a competing DM1 drug reportedly failed in a Phase 3 trial. The result may have increased concern about the difficulty of demonstrating meaningful clinical benefit in DM1 and raised the risk profile ahead of Dyne’s own data release. DM1 rival trial news
• Negative Sentiment: No company-specific negative clinical result was confirmed in the reports. However, the absence of new efficacy data today, combined with uncertainty surrounding the upcoming one-year results and the delay until Q1 2027 for registrational-cohort topline data, left DYN vulnerable to profit-taking and risk reduction. Dyne share decline report

Wall Street Analyst Weigh In

DYN has been the subject of a number of recent analyst reports. Raymond James Financial reaffirmed a “strong-buy” rating and set a $37.00 target price on shares of Dyne Therapeutics in a research report on Tuesday. Royal Bank Of Canada increased their target price on Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Morgan Stanley dropped their target price on shares of Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a research report on Friday, July 31st. Finally, Sanford C. Bernstein increased their price target on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.17.

Institutional Trading of Dyne Therapeutics

Several institutional investors have recently made changes to their positions in the business. Hilton Head Capital Partners LLC acquired a new position in Dyne Therapeutics in the first quarter worth about $26,000. Strs Ohio acquired a new stake in Dyne Therapeutics during the fourth quarter valued at approximately $51,000. Allworth Financial LP bought a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at approximately $62,000. Aster Capital Management DIFC Ltd acquired a new position in shares of Dyne Therapeutics in the 4th quarter worth approximately $84,000. Finally, Steward Partners Investment Advisory LLC lifted its position in shares of Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock worth $95,000 after buying an additional 2,465 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.